Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryJun282010	Fate Therapeutics Receives Red Herring's North America 100 Award for Advancing Stem Cell Technology and New Medicines San Diego, CA and Ottawa, Canada – Fate Therapeutics, Inc. announced today that the Company received Red Herring’s North America 100 award, a prestigious list honoring the year’s most promising private and innovative companies from the North American business region. Read All »	View HTML Fate Therapeutics Receives Red Herring’s North America 100 Award for Advancing Stem Cell Technology and New Medicines 189.8 KB
Toggle SummaryOct142010	Fate Therapeutics Announces Collaboration with BD to Develop and Commercialize Induced Pluripotent Stem Cell Technology San Diego, CA and Ottawa, Canada (October 14, 2010) – Fate Therapeutics, Inc. has forged a collaboration and license agreement with BD (Becton, Dickinson and Company), a leading global medical technology company, through its BD Biosciences segment, for the joint development and worldwide Read All »	View HTML Fate Therapeutics Announces Collaboration with BD to Develop and Commercialize Induced Pluripotent Stem Cell Technology 12.6 KB
Toggle SummaryFeb212011	Fate Therapeutics Announces Emerging Data From Proof-Of-Concept FT1050 Clinical Trial and Receives Orphan Drug Designation Encouraging Phase 1b Clinical Data Presented at 2011 BMT Tandem Meetings Read All »	View HTML Fate Therapeutics Announces Emerging Data From Proof-Of-Concept FT1050 Clinical Trial and Receives Orphan Drug Designation 12.6 KB
Toggle SummaryFeb212011	Fate Therapeutics Announces Encouraging Clinical Results and Change in Management Fate Therapeutics announces encouraging clinical results and change in management San Diego, CA – February 21, 2011 – In parallel with announcing encouraging clinical data at the 2011 BMT Tandem Meetings from its ongoing proof-of-concept FT1050 Phase 1b trial, Fate Therapeutics Read All »	View HTML Fate Therapeutics announces encouraging clinical results and change in management 12.6 KB
Toggle SummaryMay092011	Takeda Ventures Makes Strategic Investment in Fate Therapeutics Joins Strategic Investor Syndicate of Fate that Includes Four Pharmaceutical Companies Read All »	View HTML Takeda Ventures makes strategic investment in Fate Therapeutics 15.1 KB
Toggle SummaryNov162011	Fate Therapeutics Strengthens its iPSC Platform Secures U.S. Patent to Novel Small Molecule Modulator of Pluripotent Stem Cells Read All »	View HTML Fate Therapeutics strengthens its iPSC platform 10 KB
Toggle SummaryDec082011	Fate Therapeutics Secures Foundational Patent for IPS Cell Programming U.S. Patent Covers Key Compositions Used in the Generation of Human Induced Pluripotent Stem Cells Read All »	View HTML Fate Therapeutics secures foundational patent for IPS cell programming 136.2 KB
Toggle SummaryDec132011	Fate Therapeutics Announces Promising Data From Phase 1B Study of ProHema at the 2011 American Society of Hematology Annual Conference Data Support the Potential Benefit of a Novel Ex Vivo Cell Modulation Approach to Improving Engraftment in Patients Undergoing Umbilical Cord Blood Transplantation Read All »	View HTML Fate Therapeutics announces promising data from Phase 1B study of ProHema at the 2011 American Society of Hematology Annual Conference 15.3 KB
Toggle SummaryDec142011	Fate Therapeutics Announces the Appointment of William H. Rastetter as Chairman and Interim CEO San Diego, CA – Fate Therapeutics, Inc. announced today that it has appointed William H. Rastetter Ph.D. as Chairman and Interim Chief Executive Officer. Dr. Rastetter served as Chief Executive Officer of IDEC Pharmaceuticals from December 1986 through November 2003, and as Chairman from May Read All »	View HTML Fate Therapeutics announces the appointment of William H. Rastetter as Chairman and Interim CEO 188.1 KB
Toggle SummaryJun112012	Fate Therapeutics and BD Biosciences Launch BD SMC4 to Improve Cellular Reprogramming and IPS Cell Culture Applications San Diego, CA – Fate Therapeutics, Inc. in collaboration with BD Biosciences, a segment of BD (Becton, Dickinson and Company), today announced the introduction of the first induced pluripotent stem cell (iPSC)-related product resulting from the collaboration between the two companies. Read All »	View HTML Fate Therapeutics and BD Biosciences Launch BD SMC4 to Improve Cellular Reprogramming and IPS Cell Culture Applications 11.3 KB

DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.